Accepted for Publication: June 22, 2022.
Published: August 22, 2022. doi:10.1001/jamanetworkopen.2022.27995
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Damjanovic A et al. JAMA Network Open.
Corresponding Author: Monica M. Parker, PhD, Wadsworth Center, New York State Department of Health, David Axelrod Institute, 120 New Scotland Avenue Albany, NY 12208 (monica.parker@health.ny.gov).
Author Contributions: Drs Damjanovic and Styer had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Damjanovic and Styer contributed equally to this work and share first authorship of this work. Drs Caggana and Parker served equally as principal investigators for this study.
Concept and design: Damjanovic, Styer, Caggana, Parker.
Acquisition, analysis, or interpretation of data: Damjanovic, Styer, Nemeth, Yauney, Rock, Bievenue, Hoen, Ehrbar, Kay, Parker.
Drafting of the manuscript: Damjanovic, Styer, Caggana, Parker.
Critical revision of the manuscript for important intellectual content: Damjanovic, Styer, Nemeth, Yauney, Rock, Bievenue, Hoen, Ehrbar, Kay, Parker.
Statistical analysis: Damjanovic, Styer, Ehrbar.
Obtained funding: Caggana.
Administrative, technical, or material support: Nemeth, Yauney, Rock, Bievenue, Hoen, Kay.
Supervision: Styer, Parker.
Conflict of Interest Disclosures: Dr Caggana reported receiving grants from the CDC during the conduct of the study. Dr Parker reported receiving grants from the National Cancer Institute and the CDC during the conduct of the study and subcontract support from the National Heart, Lung, and Blood Institute via the University of Vermont, contract support from the Association of Public Health Laboratories for HIV Reference Center Testing, contract support from City University of New York for hepatitis C virus testing, and contract support from New York University for hepatitis C virus sequencing outside the submitted work. No other disclosures were reported.
Funding/Support: This study was supported by the CDC Foundation through contributions to its Emergency Response Fund. Dr Damjanovic, Ms Yauney, and Ms Nemeth were supported by cooperative agreement NU50CK000516 with the CDC. Mr Ehrbar was supported by Serological Sciences Network grant U01CA260508 from the National Cancer Institute.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: The members of the Wadsworth Center’s Newborn Screening Laboratory and Bloodborne Viruses Laboratory assisted with retrieving and punching blood spot cards. Andrew Bentley, BS, Wadsworth Center Multimedia Services, provided the New York State regional map. Jill Taylor, PhD, Association of Public Health Laboratories, and Dale Morse, MD, Emory University, provided valuable contributions to the initial concept of the study. Compensation was not provided for any of these individuals.
4.Qu
J , Wu
C , Li
X ,
et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Clin Infect Dis. 2020;71(16):2255-2258. doi:
10.1093/cid/ciaa489
PubMedGoogle ScholarCrossref 8.Valentine-Graves
M , Hall
E , Guest
JL ,
et al. At-home self-collection of saliva, oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and serology: Post-collection acceptability of specimen collection process and patient confidence in specimens.
PLoS One. 2020;15(8):e0236775. doi:
10.1371/journal.pone.0236775PubMedGoogle ScholarCrossref 9.Schultz
JS , McCarthy
MK , Rester
C ,
et al. Development and validation of a multiplex microsphere immunoassay using dried blood spots for SARS-CoV-2 seroprevalence: application in first responders in Colorado, USA.
J Clin Microbiol. 2021;59(6):e00290-21. doi:
10.1128/JCM.00290-21PubMedGoogle ScholarCrossref 10.Styer
LM , Hoen
R , Rock
J ,
et al. High-throughput multiplex SARS-CoV-2 IgG microsphere immunoassay for dried blood spots: a public health strategy for enhanced serosurvey capacity.
Microbiol Spectr. 2021;9(1):e0013421. doi:
10.1128/Spectrum.00134-21
PubMedGoogle ScholarCrossref 14.Styer
LM , Miller
E , Rock
J ,
et al. Newborn testing reveals high HCV seroprevalence in pregnant women from New York State. Presented at: Retroviruses and Opportunistic Infections; March 8-11, 2020 2020; Boston, Massachusetts.
15.Lumley
SF , Wei
J , O’Donnell
D ,
et al; Oxford University Hospitals Staff Testing Group. The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers.
Clin Infect Dis. 2021;73(3):e699-e709. doi:
10.1093/cid/ciab004
PubMedGoogle ScholarCrossref 17.Nir
O , Schwartz
A , Toussia-Cohen
S ,
et al. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy.
Am J Obstet Gynecol MFM. 2022;4(1):100492. doi:
10.1016/j.ajogmf.2021.100492
PubMedGoogle ScholarCrossref 20.Breslin
N , Baptiste
C , Gyamfi-Bannerman
C ,
et al. Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals.
Am J Obstet Gynecol MFM. 2020;2(2):100118. doi:
10.1016/j.ajogmf.2020.100118
PubMedGoogle ScholarCrossref 23.Pathela
P , Crawley
A , Weiss
D ,
et al; NYC Serosurvey Team. Seroprevalence of severe acute respiratory syndrome coronavirus 2 following the largest initial epidemic wave in the United States: findings from New York City, 13 May to 21 July 2020.
J Infect Dis. 2021;224(2):196-206. doi:
10.1093/infdis/jiab200
PubMedGoogle ScholarCrossref 24.Shimabukuro
TT , Kim
SY , Myers
TR ,
et al; CDC v-safe COVID-19 Pregnancy Registry Team. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons.
N Engl J Med. 2021;384(24):2273-2282. doi:
10.1056/NEJMoa2104983
PubMedGoogle ScholarCrossref 26.Kashani-Ligumsky
L , Lopian
M , Cohen
R ,
et al. Titers of SARS CoV-2 antibodies in cord blood of neonates whose mothers contracted SARS CoV-2 (COVID-19) during pregnancy and in those whose mothers were vaccinated with mRNA to SARS CoV-2 during pregnancy.
J Perinatol. 2021;41(11):2621-2624. doi:
10.1038/s41372-021-01216-1
PubMedGoogle ScholarCrossref 28.van den Berg
JP , Westerbeek
EA , Smits
GP , van der Klis
FR , Berbers
GA , van Elburg
RM . Lower transplacental antibody transport for measles, mumps, rubella and varicella zoster in very preterm infants.
PLoS One. 2014;9(4):e94714. doi:
10.1371/journal.pone.0094714
PubMedGoogle ScholarCrossref 32.Simon
E , Gouyon
JB , Cottenet
J ,
et al. Impact of SARS-CoV-2 infection on risk of prematurity, birthweight and obstetric complications: a multivariate analysis from a nationwide, population-based retrospective cohort study.
BJOG. 2022;129(7):1084-1094. doi:
10.1111/1471-0528.17135
PubMedGoogle ScholarCrossref